OPTIC data showed a single injection of Ixo-vec gene therapy cut annualized anti-VEGF injections 87%, with sustained ...
New real-world data from ASRS 2026 show nearly 40% of wet AMD patients go 180+ days without anti-VEGF treatment within a year ...
Presenters highlight clinical insights and lessons from recent trial data and surgical experience On efficacy, Regillo said ...
How equitably are glaucoma medications being dispensed across a universal health care system, and how have prescribing ...
An AI platform that screens patient charts for clinical trial eligibility increased randomization by 37.5% and cut screen ...
A real-world Vestrum database analysis found pegcetacoplan was linked to better visual acuity outcomes in geographic atrophy, ...
Initiating aflibercept 8 mg or faricimab as a first-line therapy was associated with longer treatment intervals and superior ...
REMAIN data show MCO-010 optogenetic therapy delivered durable ~3-line vision gains in retinitis pigmentosa regardless of ...
Arshad M. Khanani, MD, MA, discusses phase 3 SOL-1 data showing axitinib sustained vision in wet AMD for 9-12 months after 1 ...
Introducing Nicholas Riina, MS. Nicholas Riina, MS, had his eye on the prize early on, growing up in a family in which he was ...
OLN324 outperformed faricimab on anatomic outcomes as early as week 1 in the JADE trial, with no cases of intraocular ...
As director of clinical trials, Sheth has served as principal investigator on more than 100 clinical trials, advancing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results